{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:30Z","timestamp":1790812710106,"version":"4.1.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Prax"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Menschen mit Demenz werden in Deutschland \u00fcberwiegend ambulant durch Haus\u00e4rzte und neurologisch-psychiatrische Fach\u00e4rzte versorgt; neben Antidementiva werden Antipsychotika, Antidepressiva und Benzodiazepine\/Z-Substanzen vor allem bei Verhaltenssymptomen (BPSD) eingesetzt.<\/jats:p>\n                  <jats:p>In einer retrospektiven Trendanalyse der IQVIA Disease Analyzer Datenbank wurden Demenzpatienten aus 389 haus\u00e4rztlichen und 77 fach\u00e4rztlichen Praxen (2016\u20132025) eingeschlossen. Bestimmt wurde der j\u00e4hrliche Anteil mit\u22651 Verordnung je Arzneimittelgruppe.<\/jats:p>\n                  <jats:p>Der Antidementiva-Anteil stieg bei Haus\u00e4rzten von 14,7% auf 17,3% und sank bei Fach\u00e4rzten von 49,6% auf 40,9%. Antipsychotika nahmen in beiden Sektoren zu, Antidepressiva blieben stabil, Benzodiazepine\/Z-Substanzen gingen zur\u00fcck.<\/jats:p>\n                  <jats:p>Es bestehen stabile sektorale Unterschiede. Der Anstieg antipsychotischer Verordnungen trotz bekannter Risiken unterstreicht die Bedeutung von BPSD und regelm\u00e4\u00dfiger Nutzen-Risiko-Abw\u00e4gungen.<\/jats:p>","DOI":"10.1055\/a-2922-2608","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:59:57Z","timestamp":1786575597000},"source":"Crossref","is-referenced-by-count":0,"title":["Entwicklung der Pharmakotherapie von Menschen mit Demenz in Deutschland 2016-2025: Langfristige Trends in der haus\u00e4rztlichen und neurologisch-psychiatrischen Versorgung"],"prefix":"10.1055","author":[{"given":"Jens","family":"Bohlken","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Sozialmedizin, Arbeitsmedizin und Public Health (ISAP), Medizinische Fakult\u00e4t der Universit\u00e4t Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[{"name":"Epidemiology, IQVIA Germany, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"G Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"G Livingston","year":"2024","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"H C Kales","year":"2015","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"J Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e076268","DOI":"10.1136\/bmj-2023-076268","article-title":"Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study","volume":"385","author":"PL H Mok","year":"2024","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"L S Schneider","year":"2005","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia","volume":"72","author":"D T Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e2537551","DOI":"10.1001\/jamanetworkopen.2025.37551","article-title":"Benzodiazepine or antipsychotic use and mortality risk among patients with dementia in hospice care","volume":"8","author":"L B Gerlach","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JAD-140354","article-title":"Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-trial","volume":"42","author":"T Eichler","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"ref15","first-page":"1173","article-title":"Association between comorbidities and dementia diagnosis in German primary care practices","volume":"65","author":"B Michalowsky","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-0043-110032","article-title":"Diagnose- und Verordnungsverhalten von Haus- und Fach\u00e4rzten bei Patienten mit Demenz 2005 und 2015 in Deutschland","volume":"45","author":"J Bohlken","year":"2018","journal-title":"Psychiat Prax"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1017\/S1041610215002082","article-title":"Risk factors for dementia diagnosis in German primary care practices","volume":"28","author":"A Booker","year":"2016","journal-title":"Int Psychogeriatr"},{"key":"ref18","first-page":"514","article-title":"Health care for people with dementia in Germany: current practice and future challenges","volume":"89","author":"P Hessmann","year":"2018","journal-title":"Nervenarzt"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/a-2370-1933","article-title":"Alzheimer-Demenz und Antidementiva-Verordnungen 2010\u20132021 in 357 Hausarzt- und 71 Facharztpraxen","volume":"52","author":"J Bohlken","year":"2025","journal-title":"Psychiat Prax"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.euroneuro.2015.09.014","article-title":"Pharmacotherapy of dementia in Germany: results from a nationwide claims database","volume":"25","author":"J Bohlken","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"W Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/brainsci16010115","article-title":"Real-world evidence for psychiatric disorders from the German Disease Analyzer database: a narrative review","volume":"16","author":"K Kostev","year":"2026","journal-title":"Brain Sci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"80.e1","DOI":"10.1016\/j.jamda.2010.10.004","article-title":"Hertogh CMPM, van Marum RJ. Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers","volume":"13","author":"E Corneg\u00e9-Blokland","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/a-1394-2412","article-title":"Unerw\u00fcnschte Arzneimittelwirkungen in der Gerontopsychiatrie","volume":"49","author":"J Seifert","year":"2022","journal-title":"Psychiat Prax"},{"key":"ref25","first-page":"e003821","article-title":"Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions","volume":"3","author":"B Guthrie","year":"2013","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F","article-title":"Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments","volume":"16","author":"M Margallo-Lana","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s002280100348","article-title":"Psychotropic drug use in nursing homes: diagnostic indications and variations between institutions","volume":"57","author":"S Ruths","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","first-page":"521","article-title":"Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities","volume":"32","author":"A Vasudev","year":"2015","journal-title":"Drugs Aging"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/a-2515-9576","article-title":"DemStepCare: Risikostratifizierte Unterst\u00fctzung der ambulanten Demenzversorgung \u2013 Bewertung aus Angeh\u00f6rigenperspektive","volume":"52","author":"F Klein","year":"2025","journal-title":"Psychiat Prax"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer disease","volume":"388","author":"C H van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"J R Sims","year":"2023","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"J Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"101757","DOI":"10.1016\/j.lanepe.2026.101757","article-title":"From target engagement to treatment governance: the evolving role of amyloid PET in anti-amyloid therapy","volume":"67","author":"M Filippi","year":"2026","journal-title":"Lancet Reg Health Eur"}],"container-title":["Psychiatrische Praxis"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2922-2608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:32:05Z","timestamp":1790811125000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2922-2608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1055\/a-2922-2608","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0303-4259","1439-0876"],"issn-type":[{"value":"0303-4259","type":"print"},{"value":"1439-0876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}